3SBio acquires pegsiticase global rights from EnzymeRx for $6.

It has been shown to profoundly lower the crystals when administered as by intravenous infusion and intramuscular injection, and was safe and well-tolerated in a pair of recent phase I clinical studies sponsored by EnzymeRx. Pegsiticase provides received Orphan Medication designation from the FDA for refractory gout, tumor lysis Lesch-Nyhan and syndrome Syndrome. Related StoriesSRS microscope technology provides surgeons real-period microscopic vision of brain tumorsUCSD researchers develop brand-new computational strategy to find tumor-shrinking moleculesChemotherapy treatment can donate to long-term neurocognitive deficits in pediatric mind tumor survivors 3SBio intends to build up pegsiticase in China and can seek partnerships for advancement outside of China.Related StoriesCornell biomedical engineers develop 'very natural killer cells' to destroy cancers cells in lymph nodesOvarian tumor patients with a brief history of oral contraceptive use have better outcomesNew results reveal association between colorectal cancers and melanoma drug treatmentIn the four-arm trial, researchers randomly assigned 1,803 premenopausal patients with early-stage, estrogen receptor -positive breast malignancy to get tamoxifen or anastrazole or each one of these two remedies with zoledronic acid for 3 years. In the original report, presented in 2008, Gnant and his colleagues reported significantly improved disease-free survival. The most recent long-term data, at 84 weeks after treatment, revealed a 28 % reduced risk for recurrence and a 36 % reduction in risk for death among patients treated with zoledronic acid.